Long road to a comeback: Financial expert analyzes the current situation with Bayer's shares

Long road to a comeback: Financial expert analyzes the current situation with Bayer's shares

According to a report from www.4investors.de, there is a long road to a comeback for Bayer's shares. Bayer shares have started a small recovery movement in the last two trading days, but the price increase is still not significant. From a chart perspective, only small hurdles have been overcome so far, and further buy signals are necessary to confirm a recovery. Fundamental risks such as the group's difficult operational situation, the possible reduction or cancellation of the dividend and the legal dispute over glyphosate in the USA also contribute to the uncertainty. The failed clinical trial with the drug candidate Asundexian has also left a big hole in Bayer's future plans. The situation therefore remains uncertain and a comeback for the share price is not yet in sight.

Chart technical data shows that the last share price is 32,390 euros, and the Bollinger Bands, EMA 20, EMA 50 and EMA 200 provide further information about the price development.

The uncertain situation of Bayer's shares may lead to increased volatility and uncertainty in the market. This can complicate the investment and trading process for investors. It is important to continue to closely monitor developments at Bayer and the associated risks in the market.

Source: www.4investors.de